Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-blind, Prospective Clinical Trial to Evaluate the Clinical Performance of EarlyTect® Bladder Cancer Test in the Urine DNA for Detecting Bladder Cancer Among Hematuria Patients

NCT05220189 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT05220189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-blind, Prospective Clinical Trial to Evaluate the Clinical Performance of EarlyTect® Bladder Cancer Test in the Urine DNA for Detecting Bladder Cancer Among Hematuria Patients
Lead sponsor
Asan Medical Center
Phase
Observational
Overall status
Unknown status
Start date
February 3, 2022
Completion date
January 31, 2024
Enrollment
1,549 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, hematuria; benign